On December 7th, Guangzhou Pharmaceutical Group's Guangzhou Pharmaceutical International (Macau) Qingzhou Pharmaceutical Factory in Macau passed the examination of Macao Drug Administration and obtained the good manufacturing practice (GMP) certification of traditional Chinese medicine. It is the first certified Chinese medicine manufacturing enterprise since the implementation of Macao's Law on the Registration of Pharmaceutical Activities of Traditional Chinese Medicine and Chinese Patent Medicines and the inauguration of Macao Drug Administration.

Guangyao Group's Baiyunshan Compound Banlangen Granule (low sugar) was successfully approved for Macao Chinese patent medicine registration certificate, which is the first oral innovative new drug approval issued by the same name since the implementation of Macao's Law on the Registration of Traditional Chinese Medicine and Chinese Patent Medicine and the unveiling of Macao Drug Administration.

Chinese medicine has always been one of the important ways to promote the deep cooperation of Guangdong-Hong Kong-Macao Greater Bay Area industry. In 2020, with the goal of promoting Guangdong-Macao cooperation, helping Macao's moderate and diversified economic development and accelerating the internationalization of Chinese medicine, GPHL set up an international headquarters in Macao, and quickly established a production base of Chinese patent medicines that meets GMP standards. Recently, GPHL obtained the license for manufacturing Chinese traditional medicines, and is gradually promoting Chinese patent medicines made in Macao to the world. Nanfang Daily reported this and interviewed Huang Yin, the post-90s youth of Macao and the exclusive agent of Guangzhou Pharmaceutical Group in Macao.

Guangzhou Pharmaceutical International (Macau) Qingzhou Pharmaceutical Factory, a subsidiary of Guangzhou Pharmaceutical Group, has obtained the license for manufacturing traditional Chinese medicine, which is the first license for manufacturing oral solid preparations of traditional Chinese medicine (including liniments for external use) in Macau issued by the Drug Administration of the Macao Special Administrative Region Government. It is worth mentioning that in the same type of license, the license obtained by Guangzhou Pharmaceutical International (Macau) Qingzhou Pharmaceutical Factory contains the most dosage forms of Chinese patent medicines.

On August 3, 2022, this year's Fortune Global 500 list was officially released. It is worth noting that GPHL's performance is still outstanding, and it has been on the list for the second year in a row. After becoming the first Fortune 500 company with Chinese medicine as its main business last year, it has reached a new high this year, ranking 467th, up one place from last year, and its international influence is constantly improving. In the previous list released by Brand Finance, GPHL ranked 18th among the most valuable pharmaceutical brands in the world with a brand value of US$ 2.1 billion, which was one place higher than last year, and its brand value growth rate ranked among the top pharmaceutical brands in China.

According to the Macau Daily, Ho Iat Seng, Chief Executive of the Macao Special Administrative Region (SAR) ended his visit to Foshan on January 9, and then went to Guangzhou to continue his trip. After arriving in Guangzhou, he first visited a Chinese medicine company in Guangzhou (Baiyunshan Hutchison Whampoa Chinese Medicine Co., Ltd., a subsidiary of Guangzhou Pharmaceutical Group), which is the largest single Chinese medicine manufacturer in South China. Zhang Xin, Vice Governor of Guangdong Province, and Wen Guohui, Mayor of Guangzhou, accompanied the Chief Executive during the inspection. During the inspection, the Chief Executive and his party listened to the report on the development of the group and its participation in Guangdong-Macao cooperation.

Core Tip: Guangzhou Pharmaceutical Group (Macau) International Development Industry Co., Ltd. was inaugurated in Macau on the 3rd, which will deepen the cooperation in the field of medicine in Guangdong-Hong Kong-Macao Greater Bay Area, help Macao's moderate and diversified economic development, and accelerate the internationalization of Guangzhou Pharmaceutical Group. Guangzhou Pharmaceutical Group (Macau) International Development Industry Co., Ltd. was inaugurated in Macau on the 3rd, which will deepen Guangdong-Hong Kong-Macao Greater Bay Area's cooperation in the field of medicine, help Macao's moderate and diversified economic development, and accelerate the internationalization of Guangzhou Pharmaceutical Group.